Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners keep buying prevention, livestock producers cannot casually ignore infestations, and outbreaks can turn a routine category into an urgent one.
Convenience is becoming the real product
The important shift is away from chasing parasites after the fact and toward preventing them with less hassle. Merck Animal Health's BRAVECTO QUANTUM, approved by the FDA in July 2025, offers dogs eight to 12 months of flea and tick protection through an extended-release injection. That changes the sales conversation. A monthly reminder is easy to forget; a treatment that potentially covers most of a year has a much cleaner compliance pitch.
Elanco has been leaning into that same reality from another direction. Its Advantage Collar for Dogs arrived in April 2026 with four months of flea and tick protection plus mosquito repellency. Credelio Quattro, meanwhile, combines four active ingredients and had reached $100 million in net sales by September 2025, according to the notes. That is the sort of early commercial traction investors ought to notice. A broader product can command attention, but only if customers understand why it is worth paying for and veterinarians stay comfortable recommending it.
- Longer duration can improve adherence and make prevention more routine.
- Combination treatments widen the addressable parasite problem without requiring several products.
- Home delivery and automatic replenishment can make recurring pet-health spending stickier.
Zoetis already shows the category's financial weight. Its 2025 parasiticide revenue was $2.341 billion, up from $2.153 billion in 2024, or roughly one-quarter of total revenue. Merck's BRAVECTO line generated $1.1 billion. Those are not side businesses tucked in a corporate drawer; they are serious franchises with established distribution, veterinary relationships, and plenty to defend.
Screwworm is the uncomfortable catalyst
New World screwworm has put a different kind of fuel under the market. As of November 3, 2026, the FDA had issued 16 Emergency Use Authorizations and three conditional approvals for animal drugs addressing the pest. That includes products for cattle and companion animals: Zoetis' Dectomax-CA1 received conditional approval in September 2025, Merck's EXZOLT CATTLE-CA1 followed that December, and Boehringer Ingelheim's Ivomec received an Emergency Use Authorization in February 2026.
Emergency authorizations can create opportunity, but they are not the same thing as a permanent, carefree revenue stream.
That distinction matters. The regulatory response demonstrates demand and opens a route for companies with useful products already on the shelf. It also tells investors that disease events can reorder priorities in a hurry. Still, nobody should lazily annualize an emergency situation. Treatment patterns, geography, regulatory terms, and the duration of an outbreak all matter. Merck and Zoetis have both gained dog-related screwworm authorizations in 2026, but the eventual economic payoff remains a matter of execution, not a gift from the heavens.
Resistance is where the easy story breaks down
This market has a nasty built-in contradiction. The more routinely effective products are used, the more carefully manufacturers, veterinarians, and producers need to guard against resistance. The FDA specifically encouraged cattle producers in February 2026 to use antiparasitic drugs only when medically necessary and within comprehensive management strategies. That is sensible stewardship, but it means volume growth cannot be viewed as an unlimited pump.
Food-animal products also face residue limits, withdrawal periods, manufacturing scrutiny, labeling rules, and country-by-country regulatory differences. Add generic competition, raw-material swings, and the cost of developing new actives, and this is no sleepy consumer-products aisle. A longer-lasting formulation may strengthen pricing and loyalty, yet it can also mean fewer dosing events. Companies need to win on value per animal, clinical usefulness, and channel control, not merely on the number of packages shipped.
The regional map is not standing still
North America leads today, supported by veterinary infrastructure, companion-animal spending, livestock production, and intense FDA activity. Asia-Pacific is identified as the fastest-growing region, with China, India, Japan, and Australia central to the opportunity. Boehringer Ingelheim's April 2026 NexGard SPECTRA launch in India is one concrete sign of that push. Europe is broadening approved protection, while Mexico's BRAVECTO screwworm approval shows the problem and the commercial response crossing borders.
My read is simple: this is an attractive, defensible animal-health category, provided investors resist the urge to treat every regulatory headline as permanent upside. The better operators will pair long-duration products with responsible use, navigate local approvals without tripping over themselves, and keep innovating before resistance erodes the old playbook. The market forecast is encouraging. The hard part, as usual, is earning it.